卡培他滨与顺铂联合治疗晚期胆管癌的二线化疗
Combination Therapy with Capecitabine and Cisplatin as Second-Line Chemotherapy for Advanced Biliary Tract Cancer.
作者信息
Jung Jang Han, Lee Hee Seung, Jo Jung Hyun, Cho In Rae, Chung Moon Jae, Bang Seungmin, Park Seung Woo, Song Si Young, Park Jeong Youp
机构信息
Division of Gastroenterology, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Republic of Korea.
出版信息
Chemotherapy. 2017;62(6):361-366. doi: 10.1159/000479425. Epub 2017 Aug 26.
BACKGROUND/AIMS: Palliative chemotherapy is the main treatment for advanced biliary tract cancer (BTC). However, there is a lack of established second-line chemotherapy to treat disease progression after first-line chemotherapy. We examined combination therapy with capecitabine and cisplatin for advanced BTC as a second-line regimen.
METHODS
We analyzed the medical records of 40 patients diagnosed with BTC who received palliative second-line chemotherapy with capecitabine and cisplatin.
RESULTS
The median overall survival from the start of second-line chemotherapy was 6.3 months. The median overall survival from diagnosis was 17.9 months. The median progression-free survival during second-line chemotherapy was 2.3 months. Nine (30%) patients experienced adverse events of grade ≥3. Eastern Cooperative Oncology Group performance score was an independent predictor of adverse events.
CONCLUSIONS
Combination therapy with capecitabine and cisplatin may be an option for second-line chemotherapy in some of patients with advanced BTC.
背景/目的：姑息化疗是晚期胆管癌（BTC）的主要治疗方法。然而，目前缺乏成熟的二线化疗方案来治疗一线化疗后疾病进展的情况。我们研究了卡培他滨和顺铂联合治疗晚期BTC作为二线方案的疗效。
方法
我们分析了40例被诊断为BTC并接受卡培他滨和顺铂姑息性二线化疗患者的病历。
结果
从二线化疗开始计算的中位总生存期为6.3个月。从诊断开始计算的中位总生存期为17.9个月。二线化疗期间的中位无进展生存期为2.3个月。9例（30%）患者出现≥3级不良事件。东部肿瘤协作组体能状态评分是不良事件的独立预测因素。
结论
卡培他滨和顺铂联合治疗可能是部分晚期BTC患者二线化疗的一种选择。
Zotero 插件